This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Absence seizures, common in children, present as brief lapses in awareness, often mistaken for daydreaming. These non-convulsive seizures involve staring spells and subtle movements, potentially ...
Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...
Dr. Marcie Hall answers the question: 'Staring Into Space vs. Absence Seizure?' Oct. 23, 2008 -- Question: How do you tell the difference between staring into space "as if in his/her own world" and an ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
TipRanks on MSN
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures
Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...
Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback